Laboratory Corporation of America Holdings (LabCorp; Burlington, NC, USA) has launched “Enlighten Health Genomics,” a new business that builds on the diagnostic potential of next-generation sequencing (NGS) technology. Enlighten Health Genomics is part of LabCorp’s “Enlighten Health,” an innovation engine for provider and patient-facing services and tools that enhance treatment decisions, lower healthcare costs, and improve patient outcomes.

Enlighten Health Genomics combines LabCorp’s leading infrastructure and capabilities with a team of accomplished geneticists to offer state-of-the-art diagnostic capabilities, NGS analysis and interpretation, and informed genetic counseling.

“Enlighten Health Genomics is an important part of LabCorp’s strategy to capitalize on our unique assets, create new sources of revenue from our core capabilities, and meaningfully differentiate us from competitors,” said David P. King, LabCorp’s chairman and CEO, “The launch of this business is another tangible step in the development of Enlighten Health, our initiative to create innovative tools and capabilities to enhance patient care.”

Enlighten Health Genomics will soon introduce “ExomeReveal,” a whole exome sequencing testing service to help provide earlier and improved genetic diagnosis—based on genome-wide interpretation as well as additional diagnostic information—including for children with serious childhood genetic diseases. “We believe that patients with serious genetic conditions require a thorough interpretation of their genome,” said Duke University genetics professor David Goldstein, who will chair Enlighten Health Genomics’ scientific advisory board, “Our goal is to offer innovative and affordable diagnostic solutions to broad patient populations, making genomics a routine part of clinical decisions.”